secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-207633
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q1 net loss $42.4M; FDA aligns on TSHA-102 BLA submission pathway
------------------------------------------------------------------------

- Net loss $42.4M ($0.12/sh) vs $21.5M ($0.08/sh) Q1 2025; R&D expense doubled to $33.8M on PPQ and clinical costs.
- Cash $276.6M; company expects runway into 2028.
- FDA reaffirmed alignment on TSHA-102 BLA pathway including pivotal trial design, endpoints, and potential 6-month interim submission.
- Dosing in REVEAL pivotal and ASPIRE trials on track for Q2 2026 completion; no treatment-related SAEs or DLTs to date.
- BLA-enabling PPQ campaign initiated April 2026; completion expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/0001193125-26-207633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-207633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer